tbuckley/cabot-search huggingface dataset:
POS0010 A LOWER FREQUENCY OF ST-ELEVATION MYOCARDIAL INFARCTION IN PATIENTS WITH GOUT
Authors: P. Drivelegka, L. T. H. Jacobsson, T. Zverkova Sandstrom, M. Dehlin
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Patients with gout are at increased risk of acute myocardial infarction (AMI)[1]. However, its clinical characteristics have not been previously studied. <h3>Objectives:</h3> The aim of this study was to investigate the clinical characteristics of first-ever AMI in patients with gout compared to the general population. <h3>Methods:</h3> Using data from regional and national population-based registers, we identified all patients with a diagnosis of gout at both primary and specialized care in Western Sweden and a first-ever AMI in the period 2006-2016. Each subject was matched on sex and admission year with up to 5 comparators from the general population. Clinical presentation at admission, and clinical course in gout cases and controls were compared by using logistic regression analysis. <h3>Results:</h3> We identified 1,000 patients with gout (men, 72.7%; mean age, 70.0 years) and 4,740 matched general population comparators (men, 73.5%; mean age, 71.5 years) with a first-ever AMI. Patients with gout had significantly more comorbidities compared to the general population (Table 1). At admission, patients with gout had significantly lower odds of ST-elevation myocardial infarction (STEMI) (OR, 0.84; 95%CI, 0.72-0.99) and higher odds of atrial fibrillation (AF) (OR, 1.93; 95%CI, 1.62–2.31) and severely depressed left ventricular function (OR, 1.35; 95%CI, 1.00–1.82) (Table 2). Gout patients were significantly more likely to receive treatment with continuous positive airway pressure, and less likely to undergo coronary angiography, percutaneous coronary intervention (PCI), or any revascularization during hospitalization (Table 2). The duration of hospitalization for first-ever AMI was longer in gout patients than in controls (7.5 vs 6.4 days; p-value, &lt;0.001). <h3>Conclusion:</h3> Patients with gout were significantly less likely to present with STEMI at admission for first-ever AMI compared to the general population, but they were more likely to present with AF and severely depressed left ventricular function. Furthermore, they were less likely to undergo coronary angiography and PCI during hospitalization, as compared to the general population. <h3>REFERENCES:</h3> [1] Drivelegka P, Arthritis Care Res (Hoboken). 2023 Jun;75(6):1292-1299. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1692-PARE ADHERENCE STUDY TO HERPES ZOSTER VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED RHEUMATIC DISEASES TREATED WITH JAK INHIBITORS - PATIENT PERSPECTIVES
Authors: A. Esteban-Vazquez, A. Acosta, E. Castaneda, M. Steiner, S. Munoz-Fernández
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Biologic therapies have represented a significant progress in the treatment and prognosis of patients with immune-mediated rheumatic diseases (IMRD), with their primary adverse effect being an increased risk of serious infections. Various tools, including vaccines, have been developed for infection prevention in this patient population; however, suboptimal adherence to vaccination is well-known. <h3>Objectives:</h3> To assess adherence to recombinant herpes zoster vaccination in patients with IMRD undergoing treatment with JAK inhibitors (iJAK), identify reasons for non-vaccination, and evaluate patient satisfaction following vaccination. <h3>Methods:</h3> Retrospective and descriptive study, approved by the Regional Ethics Committee of the Community of Madrid, involving telephone interviews with all iJAK patients offered vaccination in the past two years. The interviews investigated herpes zoster vaccination, satisfaction levels, and reasons for non-vaccination if applicable. <h3>Results:</h3> 68 patients were included, with 75% (50) being women, and nine (13.2%) having a history of herpes zoster (HZ). Of the participants, 63 (92.6%) received both prescribed vaccine doses, two (2.9%) received a single dose, and three (4.4%) did not get vaccinated, primarily due to not perceiving themselves as at-risk patients. The three patients who declined vaccination had a diagnosis of rheumatoid arthritis and no history of HZ. Following vaccination, 50 (78.1%) patients felt more protected, while other opinions ranged from no discernible difference to fear of adverse effects. No patient regretted being vaccinated. <h3>Conclusion:</h3> Adherence to the recommended two doses of recombinant herpes zoster vaccine in patients with immune-mediated rheumatic diseases has been high, with the majority reporting a high level of satisfaction. Effective communication between healthcare professionals and patients plays a crucial role in vaccination adherence. <h3>REFERENCES:</h3> [1] Alnaimat F, Sweis JJG, Jansz J, Modi Z, Prasad S, AbuHelal A, Vagts C, Hanson HA, Ascoli C, Novak RM, et al. Vaccination in the Era of Immunosuppression. <i>Vaccines</i>. 2023; 11(9):1446. <h3>Acknowledgements:</h3> We would like to thank to the participants who willingly contributed to this research, and to our colleagues for their support and collaboration. <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1644-PARE EVALUATION OF MODIFIABLE CARDIOVASCULAR RISK FACTORS IN PRIMARY SJOGREN SYNDROME
Authors: A. Dellal, N. Olivier, K. K. Irène, F. K. Doryne, H. Ons, R. Niariantsoa, O. Fain, J. Sellam, A. Mekinian
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Autoimmune diseases such as lupus and rheumatoid arthritis have a very significant cardiovascular risk. There are a very few studies that evaluate the cardiovascular risk during primary sjogren syndrome (pSS). <h3>Objectives:</h3> To evaluate the modifiable cardiovascular risk in primary sjogren syndrome (pSS). <h3>Methods:</h3> We conducted a retrospective study of all patients fulfilling the 2016 ACR/EULAR classification criteria for pSS. We collected the patient characteristics, age, sex, disease activity …….. current treatments and also modifiable cardiovascular risk factors s (body-mass index, systolic blood pressure, non–high-density lipoprotein cholesterol, current smoking, and diabetes). <h3>Results:</h3> 57 patients were included with a median age of 61.2 [22-87] years, among which 53 (93%) were women.The duration of disease progression of 6.7 years [2-25] and ESSDAI 3.3[0-12]. Among 52 (92.8%) with a positive labial salivary gland biopsy (LSGB), 19 (40%) Ssa postive, 10(18%) Ssb positive, 37 (66%) FR positive, and mean gammaglobulin 14.5 g/l[4.6-46.9]. About modifiable cardiovascular risk factors; BMI 27[4.6-46.9], with 49% overweight(28/57) and 23%(13/57) obese.High blood pressure in 3%(n=13), tobacco 9%(n=5), 7% diabetes 2 (n=4) and dyslipdémia 46%(n=19). Amoung 36/57 patients with a lipid profile: total cholesterol 4.64 mmol [3.09- 6.65], with 31%(n=11) having hyperCT &gt;5.20 mmol/l, and 30% associated with non-HDL cholesterol level mor than 2.58 mmol/l. Regarding tratements: all patient with hight blood pressure have a treatement, 7%(n=4) oral antidiabetics drug, and 12%(n=7) have a Cholesterol-lowering therapy. Our results confirm the frequency of modifiable cardiovascular risk in primary sjogren syndrome (pSS). Furthermore in ours series, we noted an increase of hypercholesterolaemia but not hight blood pressure[1]. All our patients with hypertension and diabetes mellitus have a treatements, but 36%(4/11) of hypercholesterolaemia not treated, 18% insufficiently treated but 30% of patients had an LDL level more than therapeutic objective for patient swith inflammatorry disease(&gt;1g/l). <h3>Conclusion:</h3> pSS is associated with an increased risk of cardiovascular risk, and requires multidisciplinary care(cardiologist, rheumatologistic and en endocrinologist). <h3>REFERENCES:</h3> [1] Cardiovascular disease risk burden in primary sjogren's syndrome: results of a population-based multicentre cohort study.E Bartoloni et al.The journal of internal médicine 2015. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1630-HPR THE NON-PHARMACOLOGICAL MANAGEMENT OF CHRONIC INFLAMMATORY RHEUMATISM: A CAP (KNOWLEDGE, ATTITUDES, AND PRACTICES) SURVEY AMONG RHEUMATOLOGISTS IN MOROCCO
Authors: F. Kronbi, H. Rkain, N. Benzine, S. Ez-Zaoui, T. Latifa, I. Bensaghir, S. Farih, R. Honsali, H. L ’heri, N. Hajjaj-Hassouni, F. Allali
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Chronic inflammatory rheumatic diseases are prevalent conditions with a wide array of pharmaceutical treatments. Nevertheless, a considerable number of patients still endure symptoms that negatively affect their quality of life. It seems crucial that rheumatologists provide personalized complementary therapies for each patient, actively involving them in their care. <h3>Objectives:</h3> This study aims to assess the knowledge, attitudes, and practices of Moroccan rheumatologists regarding the Non-Pharmacological Management (NPM) of chronic inflammatory rheumatic diseases (CIRD). <h3>Methods:</h3> A descriptive and analytical cross-sectional study was conducted within the community of Moroccan rheumatologists. A structured Google Forms questionnaire, divided into four sections, sociodemographic data of rheumatologists, knowledge, attitudes of rheumatologists, and their practices related to non-pharmacological management of CIRD was distributed to 440 rheumatologists. Responses were recorded on a Likert scale from 1 to 5, with the following coding: In the 'Knowledge (K)' section: 1=True, 2=Probable, 3=Unlikely, 4=False, 5=I don't know; In the 'Attitudes (A)' section: 1=Strongly agree, 2=Agree, 3=Neutral, 4=Disagree, 5=Strongly disagree; In the 'Practices (P)' section: 1=Always, 2=Often, 3=Sometimes, 4=Rarely, 5=Never. <h3>Results:</h3> Out of 440 questionnaires sent, 132 rheumatologists responded to the survey, resulting in a response rate of 30%. The average age of the rheumatologists was 44 ± 12 years, with 84.8% being female, and an average professional experience of 15.4 ± 12 years. The assessment results of the knowledge, attitudes, and practices of Moroccan rheumatologists in the non-pharmacological management of chronic inflammatory Rheumatism (CIRD) are presented in Table 1. <h3>Conclusion:</h3> This work provides a comprehensive overview of the knowledge, attitudes, and practices of Moroccan rheumatologists regarding the non-pharmacological management of chronic inflammatory rheumatism (CIRD). It highlights the importance of further and systematic integration of various non-pharmacological approaches to enhance the quality of life for our patients with CIRD and advocates for adopting a holistic approach to patient care <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS0162 SUPERIORITY OF PLM FOLLOWED BY RAMAN SPECTROSCOPY AS A TWO-STEPPED ANALYSIS IN SYNOVIAL FLUID CRYSTAL IDENTIFICATION
Authors: T. Niessink, M. Janssen, C. Otto, T. Jansen
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> The gold standard diagnostic measure for crystal-induced arthritis is polarized light microscopy, the application of which remains challenging for rheumatologists. Glass artefacts, small crystal sizes, amorphic deposits, and poor training in handling of the microscope affect the reliability of the outcome. Uncertainties may be problematic as the choice of treatment in individual patients is dependent on the identification. <h3>Objectives:</h3> In this study we re-evaluate (two-stepped analysis) synovial fluid samples in which the crystal identification of the rheumatologist was not certain on their polarized light microscopic diagnosis with Raman spectroscopy. Raman spectroscopy is a highly specific technique and allows for an objective identification of individual particles. <h3>Methods:</h3> 400 synovial fluid samples were evaluated by expert rheumatologists for the presence of pathological crystals (MSU and CPP). In uncertain cases, we performed an additional analysis with Raman spectroscopy (iRPoLM, Hybriscan Technologies B.V.) to either confirm the suspected crystal-based diagnosis or identify other deposits and confounders which might have confused the clinician when using the polarized light microscope. <h3>Results:</h3> Within 400 samples, the rheumatologists were uncertain of the diagnosis in 90 (22.5%). Uncertain identification of MSU (n = 30) was indeed MSU in one case (3.3%) as confirmed by Raman spectroscopy, uncertain identification of CPP (n = 45) was indeed CPP in nine cases (20%). In one case, CPP was erroneously identified as MSU, and in one case, no crystals were identified where actually CPP was present. The most prominent confounders were calcium carbonate (calcite, dolomite) crystals, which were present in 34.4% of all samples with uncertain identifications. Microplastics were present in 31.1% of all samples. Table 1 gives an overview of all results. <h3>Conclusion:</h3> We here demonstrate that an uncertain crystal diagnosis with PLM is common and that additional analysis with Raman spectroscopy significantly improves the reliability of synovial fluid analysis due to the inherent chemical specificity of the technique. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> Tom Niessink: None declared, Matthijs Janssen Crystalytics B.V., Cees Otto Hybriscan Technologies B.V., Tim Jansen Crystalytics B.V.
AB1689-PARE THE ROLE OF PHYSICAL THERAPY IN ADULT CHRONIC NONBACTERIAL OSTEITIS (CNO): PATIENTS’ AND THERAPISTS’ PERSPECTIVE
Authors: E. Winter, A. Leerling, D. Ueckert, F. Van der Giesen, T. P. M. Vliet Vlieland
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Chronic nonbacterial osteitis (CNO) is a rare musculoskeletal disease causing bone pain and functional impairment. The disease has historically been labelled as synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO)-syndrome due to its wider spectrum of inflammatory features. <h3>Objectives:</h3> We map the use and perceived effects of physical therapy (PT) for CNO, and preferences and needs regarding the provision of PT from the patients' and first-line therapists' perspectives. <h3>Methods:</h3> Cross-sectional study among the unique Dutch adult CNO cohort (patients enrolled between 1992–present). A survey on PT use that was previously employed in patients with axial spondylarthritis was adapted to align with CNO, covering the current PT-use and/or use in the past 24 months and reasons for non-use if applicable. PT-users were asked about the treatment modalities, and perceived health-related effects, satisfaction (numeric rating scale, 1-10) along with preferences for future use; their physical therapists were invited to complete a self-developed survey covering therapy details and preferences regarding information on CNO. <h3>Results:</h3> 80/195 and 14/16 patients and therapists completed the survey respectively. 41(51%) patients had used PT for CNO in the preceding 2 years. Reasons for not using PT included ineffectiveness of PT prior to this period (n=14/39, 36%), lack of physician recommendation (n=12/39, 31%), and cost concerns (n=6/39, 15%) (multiple answers possible). PT-users reported diverse methods of PT for CNO, most commonly involving passive therapy like massage (n=25/41, 61%) and joint mobilizations (n=18/41, 44%), and active therapy such as muscle strengthening and breathing exercises (n=17/41, 42% and n=20/41, 49%). PT-users were mostly, but variably satisfied (median satisfaction score 8/10, range 1-10). 51/80 (64%) patients (users and non-users combined) desired greater emphasis from their clinicians regarding the value of PT. Therapists reported to appreciate referral letters with disease and patient-specific information (n=13/14, 93%), and the opportunity to consult a therapist situated at the expert center given the rarity of the condition (n=12/14, 86%). <h3>Conclusion:</h3> Half of adult CNO patients currently use or recently used PT, which involves variable therapeutic methods. The majority of patients desire more clinical emphasis on PT, and the majority of therapists indicated a preference for more disease-specific information from the expert center to support their care. Future studies should investigate the effectiveness of CNO-tailored exercise programs to better define the role of PT in CNO management. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1555-HPR COGNITIVE FUNCTION IN SYSTEMIC SCLEROSIS: A SYSTEMATIC REVIEW
Authors: D. Karagianni, L. Sakkas
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Systemic sclerosis (SSc) is a chronic systemic disease with skin and internal organ manifestations often difficult to treat. SSc patients often complain to their doctors about memory and attention difficulties, as well as about the "tip of the tongue" phenomenon. Cognitive worsening during this chronic disease seems to be underestimated. <h3>Objectives:</h3> This study aims to review the cognitive function of SSc patients systematically. <h3>Methods:</h3> This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The search was performed in PubMed, Scopus, and ScienceDirect for English articles published from inception to 2024. The combinations of keywords used were: "systemic sclerosis", "cognitive function", "cognitive impairment" and "neuropsychological impairment". There was no limitation in age, gender, nationality, and severity of disease. Studies with perceived cognitive function, qualitative studies, and reviews were not chosen for the review. <h3>Results:</h3> A total of 4 quantitative studies with 113 SSc patients who underwent neuropsychological evaluation were included[1-4]. Neuropsychological assessments utilized in the studies were the Mini-Mental State Examination, Wechsler Deterioration Index, Symbol Digit Modalities Test, Wisconsin Card Sorting Test, Wechsler Memory Scale 3rd Edition Digit Span subtest, the Stroop ColorWord Interference Test, California Verbal Learning Test, and Benton Facial Recognition Test. Results unveiled significant deficits in verbal fluency and memory tasks, attention and information processing speed, global and complex attention, visuospatial functions, and dysexecutive syndrome. <h3>Conclusion:</h3> Although data are limited, there are significant cognitive deficits in patients with SSc and appear to impair the quality of life of these patients. <h3>REFERENCES:</h3> [1] Aligianni SΙ, et al. Low cognitive functioning and depressive symptoms in patients with rheumatoid arthritis and systemic sclerosis: a clinical study. BMC psychiatry. 2023;23(1). [2] Khedr EM, El Fetoh NA, Gamal RM, Elzohri MH, Azoz NMA, Furst DE. Evaluation of cognitive function in systemic sclerosis patients: a pilot study. Clinical rheumatology. 2020;39(5):1551-9. [3] Sakr BR, Rabea RE, Aboulfotooh AM, Kishk NA. Neurosonological and cognitive screening for evaluation of systemic sclerosis patients. Clinical rheumatology. 2019;38(7):1905-16. [4] Yilmaz N, Mollahasanoglu A, Gurvit H, Can M, Tuncer N, Inanc N, et al. Dysexecutive syndrome: a specific pattern of cognitive impairment in systemic sclerosis. Cognitive and behavioral neurology: official journal of the Society for Behavioral and Cognitive Neurology. 2012;25(2):57-62. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1528 BODY COMPOSITION AFTER NUTRITIONAL ORIENTATION IN OVERWEIGHT AND OBESE PATIENTS WITH RHEUMATIC DISEASES
Authors: F. J. Torres-Quintanilla, A. K. Garza-Elizondo, J. C. Riega-Torres, K. Salinas-Zamora, P. R. Ancer-Rodriguez, J. A. Cardenas-de la Garza, D. A. Galarza-Delgado
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Nutritional orientation should be considered a basic adjuvant to treatment of rheumatic diseases due to its potential positive effects on comorbidities. [1] It can also have a positive impact in disease activity and prevention. [2,3] <h3>Objectives:</h3> The aim of this study is to determine the body composition of overweight and obese patients with rheumatic disease before and after nutritional orientation. <h3>Methods:</h3> Retrospective, observational, comparative, cohort, single-centre study in an outpatient Rheumatology clinic. Patients with a BMI higher than 25, with diagnosis of a rheumatologic disease, with 3 nutritional assessment consultations were included. Demographics and disease diagnosis was collected from medical records. Bioelectrical impedance analysis was routinely performed with InnerScan TANITA BC-533 monitor in each nutritional consultation. Data from the first and last nutritional assessments were compared. Pregnant women were excluded. Kolmogorov-Smirnov test was used to determine variable distribution. Student's t-test or Wilcoxon test were used accordingly for comparisons. A value of p&lt;0.05 was considered statistically significant. <h3>Results:</h3> A total of 44 patients were included. Women represented 93% of the cohort. Mean age was 50.2 ± 11.2 years. Prevalence of diseases is shown in Figure 1. Body composition before and after nutritional orientation is shown in Table 1. There was no significant difference before and after nutritional orientation in BMI (31.5 ± 5.1 and 30.9 ± 5.9 Kg/m2, p= 0.25), weight (74.3, 64.7 - 87.0 and 71.8, 62.3 - 89.6 Kg, p = 0.43), total fat (31.1 ± 10.4 and 30.7 ± 11.3 Kg, p = 0.68), nor total muscle mass (42.8, 38.9 - 46.3 and 42, 38.6 - 45.8 Kg, p = 0.43). <h3>Conclusion:</h3> After 3 nutritional assessment consultations, there was no difference in body composition in overweight and obese patients with rheumatologic diseases. A longer nutritional follow-up may be needed to achieve a significant difference in BMI, weight and fat reduction, and muscle mass increase. <h3>REFERENCES:</h3> [1] Dreher M, Kosz M, Schwarting A. Körperliche. Physical activity, exercise and nutrition in rheumatism: Adjuvant treatment options for inflammatory-rheumatic diseases. <i>Orthopade</i> 2019; <b>48</b>: 917–926. [2] Nikiphorou E, Philippou E. Nutrition and its role in prevention and management of rheumatoid arthritis. <i>Autoimmun Rev</i> 2023; <b>22</b>: 103333. [3] Montoya T, Castejón ML, Muñoz-García R, Alarcón-de-la-Lastra C. Epigenetic linkage of systemic lupus erythematosus and nutrition. <i>Nutr Res Rev</i> 2023; <b>36</b>: 39–59. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>